This study suggests that β-blocker exposure prior to sepsis, especially to noncardioselective β blockers, may be associated with better outcome. The findings suggest prospective evaluation of β-blocker use in the management of sepsis.

Total of 4,086 critical care patients above 18 years old with sepsis between January 2014 and December 2018.

One thousand five hundred fifty-six patients (38%) with premorbid β-blocker exposure were identified.

Overall ICU mortality rate was 15.1%. In adjusted models, premorbid β-blocker exposure was associated with decreased ICU and hospital mortality.

The risk reduction in ICU mortality of 16% was significant.

In particular, exposure to noncardioselective β-blocker before septic episode was associated with decreased mortality.

Read More